Compare Aterian Inc (ATER) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Incyte Corporation — how do they compare? Aterian Inc trades at $0.49 (market cap $5.32M), while Incyte Corporation trades at $121.25 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 4612.8× Aterian Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.
| ATER | INCY | |
|---|---|---|
Market Cap | $5.32M | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $129.93 |
52-Week Low | $0.36 | $81.61 |
Enterprise Value | $5.90M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.48, down 2.72% on the day, with a bearish technical signal. The company reported a net loss of -$18.98M in 2025, though it has beaten EPS estimates in recent quarters. Recent news highlights a pending asset sale that could return $0.85–$1.14 per share to stockholders, subject to a special meeting vote.
The outlook hinges on the asset sale approval, offering potential upside, but ongoing operational losses and negative cash flow pose significant risks. Analyst sentiment is split evenly between Buy and Hold, reflecting uncertainty around the company's restructuring and future profitability.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
